Mattern J, Bak M, Hahn E W, Volm M
Department of Experimental Pathology, German Cancer Research Center, Heidelberg, FRG.
Cancer Metastasis Rev. 1988 Nov;7(3):263-84. doi: 10.1007/BF00047755.
This paper reviews the history of xenografts, the endpoints commonly used to evaluate response and chemotherapeutic results obtained with serially maintained human tumor xenografts from different laboratories, and discusses the potential clinical relevance of the heterotransplant model for cancer chemotherapy. Specifically, an attempt is made to correlate the published xenograft data with the clinical data. Drug testing with different types of xenotransplanted tumors has shown that the response of xenografts obtained in immune-deficient animals is comparable to that in clinical practice. In addition, xenografts of a particular tumor type are able to identify agents of known clinical activity against that disease.
本文回顾了异种移植的历史、常用于评估不同实验室连续维持的人肿瘤异种移植反应和化疗结果的终点指标，并讨论了异种移植模型在癌症化疗中的潜在临床相关性。具体而言，试图将已发表的异种移植数据与临床数据相关联。对不同类型异种移植肿瘤进行的药物测试表明，在免疫缺陷动物中获得的异种移植反应与临床实践中的反应相当。此外，特定肿瘤类型的异种移植能够识别针对该疾病具有已知临床活性的药物。
